Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

CHICAGO (Reuters) -The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Learn more about whether Alvotech or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

the US drugmaker’s second recent foray into China for a novel medicine. Under the agreement, Merck will pay $200 million up front to develop and commercialize Hengrui Pharma’s pill ...

Jiangsu Hengrui’s pill is one of many experimental LpA-blocking drugs in clinical development. The furthest along is an RNA-based medicine from Novartis that’s currently in Phase 3 testing.

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.